cabozantinib,sunitinib,nivolumab
exelixis,pfizer,bms
['9er', 'nivo', 'sunitinib', 'cm-9er']
#asco22 #kidneycancer oral abstract breakdown part 2. depth of response analysis from cm-9er study (nivo+cabo vs sunitinib) by dr. cristina suarez. goal was to see if depth of response (% reduction of baseline target lesions) is a good surrogate for long term benefit/outcomes. 
Med onc at UW/SCCA/Fred Hutch focused on melanoma and RCC, interested in patient/caregiver QOL and all things immunotherapy. All opinions are my own.